184 related articles for article (PubMed ID: 12358909)
1. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid.
Takayama N; Sato N; O'Brien SG; Ikeda Y; Okamoto S
Br J Haematol; 2002 Oct; 119(1):106-8. PubMed ID: 12358909
[TBL] [Abstract][Full Text] [Related]
2. Low concentrations of STI571 in the cerebrospinal fluid: a case report.
Petzer AL; Gunsilius E; Hayes M; Stockhammer G; Duba HC; Schneller F; Grünewald K; Poewe W; Gastl G
Br J Haematol; 2002 Jun; 117(3):623-5. PubMed ID: 12028032
[TBL] [Abstract][Full Text] [Related]
3. Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy.
Bujassoum S; Rifkind J; Lipton JH
Leuk Lymphoma; 2004 Feb; 45(2):401-3. PubMed ID: 15101732
[TBL] [Abstract][Full Text] [Related]
4. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571).
Leis JF; Stepan DE; Curtin PT; Ford JM; Peng B; Schubach S; Druker BJ; Maziarz RT
Leuk Lymphoma; 2004 Apr; 45(4):695-8. PubMed ID: 15160941
[TBL] [Abstract][Full Text] [Related]
5. Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving concepts.
Ottmann OG; Wassmann B
Best Pract Res Clin Haematol; 2002 Dec; 15(4):757-69. PubMed ID: 12617875
[TBL] [Abstract][Full Text] [Related]
6. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia.
Wolff NC; Richardson JA; Egorin M; Ilaria RL
Blood; 2003 Jun; 101(12):5010-3. PubMed ID: 12595307
[TBL] [Abstract][Full Text] [Related]
7. The ABL tyrosine kinase inhibitor STI571 (Glivec) in Philadelphia positive acute lymphoblastic leukemia - promises, pitfalls and possibilities.
Ottmann OG; Hoelzer D
Hematol J; 2002; 3(1):2-6. PubMed ID: 11960387
[No Abstract] [Full Text] [Related]
8. Src kinase signaling in leukaemia.
Li S
Int J Biochem Cell Biol; 2007; 39(7-8):1483-8. PubMed ID: 17350876
[TBL] [Abstract][Full Text] [Related]
9. Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Ronan Swords.
Swords R
Drugs; 2007; 67(17):2655-6. PubMed ID: 18034599
[No Abstract] [Full Text] [Related]
10. Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
Wernstedt P; Brune M; Andersson PO; Gustavsson B; Stockelberg D; Wadenvik H
Bone Marrow Transplant; 2002 Dec; 30(12):971-3. PubMed ID: 12476293
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ottmann OG; Wassmann B
Hematology Am Soc Hematol Educ Program; 2005; ():118-22. PubMed ID: 16304368
[TBL] [Abstract][Full Text] [Related]
12. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.
Pfeifer H; Wassmann B; Hofmann WK; Komor M; Scheuring U; Brück P; Binckebanck A; Schleyer E; Gökbuget N; Wolff T; Lübbert M; Leimer L; Gschaidmeier H; Hoelzer D; Ottmann OG
Clin Cancer Res; 2003 Oct; 9(13):4674-81. PubMed ID: 14581336
[TBL] [Abstract][Full Text] [Related]
13. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study.
Hofmann WK; de Vos S; Elashoff D; Gschaidmeier H; Hoelzer D; Koeffler HP; Ottmann OG
Lancet; 2002 Feb; 359(9305):481-6. PubMed ID: 11853794
[TBL] [Abstract][Full Text] [Related]
14. Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy.
Patel SB; Gojo I; Tidwell ML; Sausville EA; Baer MR
Leuk Lymphoma; 2011 Jul; 52(7):1211-4. PubMed ID: 21534873
[TBL] [Abstract][Full Text] [Related]
15. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
Wang L; Pearson K; Pillitteri L; Ferguson JE; Clark RE
Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Hoelzer D; Gökbuget N; Ottmann OG
Semin Hematol; 2002 Oct; 39(4 Suppl 3):32-7. PubMed ID: 12447850
[TBL] [Abstract][Full Text] [Related]
17. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.
Matsuda M; Morita Y; Shimada T; Miyatake J; Hirase C; Tanaka M; Tatsumi Y; Maeda Y; Kanamaru A
Int J Hematol; 2005 May; 81(4):307-9. PubMed ID: 15914360
[TBL] [Abstract][Full Text] [Related]
18. Imatinib for secondary Ph+ acute lymphoblastic leukemia induces response in concomitant GBM.
De Vita S; De Matteis S; Laurenti L; Chiusolo P; Sorà F; Piccirillo N; Reddiconto G; Fiorini A; Leone G; Sica S
Ann Oncol; 2006 Apr; 17(4):720-1. PubMed ID: 16263757
[No Abstract] [Full Text] [Related]
19. Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Thomas X; Dombret H
Leuk Lymphoma; 2008 Jul; 49(7):1246-54. PubMed ID: 18452076
[TBL] [Abstract][Full Text] [Related]
20. Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy.
Aichberger KJ; Herndlhofer S; Agis H; Sperr WR; Esterbauer H; Rabitsch W; Knöbl P; Haas OA; Thalhammer R; Schwarzinger I; Sillaber C; Jäger U; Valent P
Eur J Clin Invest; 2007 Oct; 37(10):808-13. PubMed ID: 17727673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]